slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 40,291-40,320
Pages 3,679
Rows per page 30
Component
40,291-40,320 of 110,355
02
This is a research note page from a short-seller report.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
03
This slide serves as a critical analysis of clinical trial integrity, specifically focusing on the SONAR trial and subsequent reporting practices.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
04
This slide serves as a critique of clinical trial design and reporting practices, specifically regarding the SONAR trial.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
05
The text highlights discrepancies in reported ESKD numbers between different sources and questions the statistical significance of the primary renal outcome.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
06
The slide uses data from the RADAR trial to challenge the validity of UACR as a reliable surrogate endpoint for kidney function.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
07
The text argues that the rapid reversal of UACR effects upon drug cessation indicates a transient hemodynamic impact rather than structural renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
08
The slide argues that the drug Atrasentan acts as a 'band-aid' by masking symptoms via surrogate endpoints without providing long-term structural benefit.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
10
The slide provides a critical analysis of a standard medical metric, highlighting its inaccuracies and limitations in clinical practice.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
11
The slide functions as a critique of clinical trial data integrity, specifically focusing on the inclusion of serum creatinine doubling and the use of inulin as a gold standard.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
12
The slide uses bar charts to show baseline vs treatment effects on GFR, ERBF, EFF, and ERVR, suggesting these metrics are influenced by blood dilution.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
13
The slide uses a table to highlight discrepancies in mortality reporting between the 'Enrichment' group and the 'Double-Blind' groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
13
The slide uses a screenshot of a third-party listing platform as evidence of potential portfolio vacancy, contrasting it with company-reported metrics.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The StruggleLoop · Iceberg1 hit
14
Includes footnotes 16-19 detailing calculation methodology and site visit observations.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The StruggleLoop · Iceberg1 hit
15
The table provides a granular view of property utilization, highlighting high vacancy rates in specific locations like Potsdamer Strasse.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The StruggleLoop · Iceberg1 hit
16
Includes a table of occupancy assessment and photographic evidence of vacancy.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
19
The slide uses a combination of a custom occupancy table and screenshots of Vivion's official tenant lists to highlight a discrepancy in disclosure.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
20
The text highlights potential financial irregularities, specifically large receivables and lack of cash flow, suggesting revenue padding.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
21
Includes financial statement excerpts for r24 Holding GmbH (formerly rent24 GmbH) for 2017-2018.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
22
The text highlights discrepancies between rent24's stated goals and observed operational reality, including failed ventures and subleasing arrangements.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
23
The slide uses footnotes to cite sources for claims about rent24's occupancy and the Fürst property valuation.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
24
Includes a photograph of a building directory as evidence of tenant occupancy; references footnotes 44 and 45.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Struggle1 hit
25
The slide uses a table to provide context for a forensic argument about asset inflation. Footnotes 46-48 provide specific source citations for the claims.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
26
The slide uses a forensic accounting approach to challenge the legitimacy of fair value gains reported by Vivion.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
28
Includes two data tables detailing pre-rent NOI and rent inflation estimates for Ribbon and Hallmark portfolios.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
29
The slide highlights potential misappropriation and conflicts of interest in property transactions.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
30
The slide functions as a forensic investigation into a specific transaction chain, highlighting the use of nominees and rapid asset flipping.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
31
Includes footnotes 63-66. The slide highlights a discrepancy between reported transaction values and subsequent fair value gains.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
33
Includes footnotes referencing external sources and valuation calculations.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
35
The slide highlights a discrepancy in square footage to identify specific property assets (Potsdamer Straße 180, 182, and 184).Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit
37
The slide uses a narrative structure to expose financial complexity and potential fraud, referencing specific entities and dates.Vivion Investments S.à.r.l. · Carson Block
Research note Short seller Beat · The Victory1 hit